Clinical trial and other flexibilities afforded sponsors during the COVID-19 pandemic may prove to be transformative to the research system eventually, but the US Food and Drug Administration is not ready to declare that today.
The pandemic functioned as a large-scale proof-of-concept effort for many clinical research innovations that sponsors and FDA officials had been advocating for implementation. Decentralized trials, remote monitoring and real-world evidence...